Ventyx Biosciences, Inc. (NASDAQ:VTYX) Receives $8.29 Average Price Target from Analysts

Ventyx Biosciences, Inc. (NASDAQ:VTYX) has received an average recommendation of “Moderate Buy” from the eight research firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $8.29.

A number of research firms recently weighed in on VTYX. Oppenheimer lowered their price target on Ventyx Biosciences from $12.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, June 6th. Wells Fargo & Company lowered their target price on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. HC Wainwright reiterated a “neutral” rating and set a $6.00 target price on shares of Ventyx Biosciences in a report on Tuesday, July 30th. Finally, Canaccord Genuity Group lowered their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Monday, August 12th.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC purchased a new position in shares of Ventyx Biosciences during the 2nd quarter worth $32,000. Tower Research Capital LLC TRC lifted its stake in shares of Ventyx Biosciences by 1,424.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 19,927 shares of the company’s stock worth $49,000 after purchasing an additional 18,620 shares during the period. Federated Hermes Inc. purchased a new position in shares of Ventyx Biosciences during the 4th quarter worth $50,000. The Manufacturers Life Insurance Company lifted its stake in shares of Ventyx Biosciences by 41.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock worth $56,000 after purchasing an additional 7,096 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ventyx Biosciences in the 2nd quarter worth $58,000. Hedge funds and other institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Price Performance

VTYX opened at $1.96 on Wednesday. The stock has a market cap of $138.51 million, a P/E ratio of -0.60 and a beta of 0.39. The stock’s 50 day simple moving average is $2.41 and its 200 day simple moving average is $4.16. Ventyx Biosciences has a 1-year low of $1.84 and a 1-year high of $38.20.

Ventyx Biosciences (NASDAQ:VTYX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.45) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. Research analysts expect that Ventyx Biosciences will post -2.14 EPS for the current fiscal year.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.